Litcius/Paper detail

A step forward for LRRK2 inhibitors in Parkinson’s disease

Patrick A. Lewis

2022Science Translational Medicine20 citationsDOIOpen Access PDF

Abstract

A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.

Topics & Concepts

LRRK2Parkinson's diseaseMedicineDiseaseInternal medicineParkinson's Disease Mechanisms and TreatmentsPlant Gene Expression AnalysisGinkgo biloba and Cashew Applications
A step forward for LRRK2 inhibitors in Parkinson’s disease | Litcius